Abstract
Glioblastoma multiforme constitutes the most common primary brain tumor and carries a grim prognosis for patients treated with conventional therapy including surgery, radiation therapy, and chemotherapy. There has been a recent revival of selective intra-arterial delivery of targeted agents for the treatment of glioblastoma multiforme. Because these agents are less toxic and their delivery leads to a higher tumor-drug concentration, this combination may provide a better outcome in patients with high-grade glioma. This article discusses early experiences in patients who received superselective intra-arterial cerebral infusion of bevacizumab, cetuximab, and temozolamide after blood-brain barrier disruption with mannitol.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Bevacizumab
-
Blood-Brain Barrier / pathology*
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / pathology
-
Cetuximab
-
Dacarbazine / administration & dosage
-
Dacarbazine / analogs & derivatives
-
Dacarbazine / therapeutic use
-
Female
-
Glioblastoma / drug therapy*
-
Glioblastoma / pathology
-
Humans
-
Infusions, Intra-Arterial
-
Male
-
Mannitol / therapeutic use
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / pathology
-
Prognosis
-
Temozolomide
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Bevacizumab
-
Mannitol
-
Dacarbazine
-
Cetuximab
-
Temozolomide